Filing Flows › Puma Biotechnology (PBYI) › Q4 2025
Puma Biotechnology (PBYI) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Feb 26, 2026
Puma Biotechnology (PBYI) reported revenue of $75.5M for the fourth quarter 2025 (Q4 2025), +28% from a year earlier and +39% from the quarter before. Operating margin was 22.7%, net earnings $13.4M (17.8% of revenue).
Puma Biotechnology, Q4 2025: revenue $75.5M (+28% year over year), operating margin 22.7%, net earnings $13.4M, operating cash flow $14.4M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $75.5M | +39% | +28% |
| Operating profit | $17.1M | +79% | +28% |
| Net earnings | $13.4M | +52% | -30% |
| Operating cash flow | $14.4M | +49% | -8% |
What changed
Revenue was $75.5M in Q4 2025, up 28% year over year and up 39% from the previous quarter. Product was the largest line at 79% of revenue.
Operating profit was $17.1M, a 22.7% margin (unchanged year over year). Of the extra revenue versus a year earlier, 23% reached operating profit, above the 23% margin then. Total costs grew 28% against revenue growth of 28%. The fastest-growing cost line was Cost of revenue (+66%). Net earnings were $13.4M, down 30% year over year. The effective tax rate was 21.4%.
Operating cash flow was $14.4M (down 8% year over year), 107% of net earnings. Non-cash charges added back $2.7M of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items used $3.3M. Capital expenditures of −$36K left free cash flow of $14.5M.
Questions
What was Puma Biotechnology's revenue in the fourth quarter 2025?
Puma Biotechnology (PBYI) reported revenue of $75.5M for the fourth quarter 2025 (Q4 2025), +28% from a year earlier and +39% from the quarter before.
Was Puma Biotechnology profitable in the fourth quarter 2025?
Operating profit was $17.1M (22.7% of revenue) and net earnings $13.4M.
Source: Puma Biotechnology 10-K on SEC EDGAR.